Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 3/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909729 | 0.78 | ADORA2A (0.44) | CDC7ADORA2AADORA1 | |
| SCHEMBL910216 | 0.78 | IMPDH2 (0.49) | PARP1CDC7ADORA2AADORA1TDP1 | |
| SCHEMBL465882 | 0.78 | SCN2A (0.47) | PARP1MAPTNPC1MAPK1L3MBTL1 | |
| SCHEMBL910231 | 0.76 | ADORA2A (0.52) | CDC7ADORA2AADORA1 | |
| SCHEMBL909732 | 0.75 | CYP1A1 (0.56) | CDC7MAPT | |
| SCHEMBL910034 | 0.74 | CDC7 (0.44) | CDC7MAPTNPC1MAPK1ADORA2A | |
| SCHEMBL4788120 | 0.72 | LRRK2 (0.56) | PARP1PKN1PKN2MAPTNPC1 | |
| SCHEMBL9387699 | 0.72 | PARP1 (0.61) | PARP1MAPTNPC1MAPK1L3MBTL1 | |
| SCHEMBL909804 | 0.72 | ADORA2A (0.48) | CDC7ADORA2AADORA1 | |
| SCHEMBL910010 | 0.72 | PIK3CG (0.51) | CDC7ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| CN-100430389-C | Inhibition of phosphoinositide 3-kinase beta | KINACIA PTY LTD (SE) | 2008-11-05 | — | — | CN | disclosed |
| CN-101260104-A | Inhibition of phosphoinositide 3-kinase beta | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
| CN-1688575-A | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD (AU) | 2005-10-26 | — | — | CN | disclosed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | PI4KB, PI4KA, PI4K2B | PARP1 878/4885CDC7 188/4885PKN1 328/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PARP1 815/4885CDC7 232/4885PKN1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.